Expanding the Therapeutic Pipeline for Treating and Preventing Alzheimer's Disease and Related Dementias: Preclinical Validation and Drug Discovery for Novel Candidate Targets (U01 Clinical Trial Not Allowed)

The National Institute on Aging (NIA), a division of the National Institutes of Health (NIH) under the U.S. Department of Health and Human Services, is preparing to release a Notice of Funding Opportunity (NOFO) for research projects aimed at expanding the therapeutic pipeline for treating and preventing Alzheimer’s Disease (AD) and Alzheimer’s Disease-Related Dementias (ADRD). This forthcoming opportunity, announced via forecast PAR-26-132, will employ the U01 cooperative agreement mechanism and does not permit clinical trials. The NIH, as the largest public funder of biomedical research in the world, continues to prioritize high-impact studies that target unmet medical needs in aging populations. This particular NOFO reflects the federal government’s strategic investment in rigorous preclinical validation and early-stage therapeutic development. This funding initiative targets early-phase research into novel drug targets for AD/ADRD, supporting the full range of small molecules, biologics, and emerging therapeutic modalities. The program's core objective is to bridge the critical gap between basic research and translational medicine by validating new candidate targets and initiating drug discovery efforts. It emphasizes rigorous scientific standards and expects applicants to present strong justification for target selection, along with preliminary data supporting the therapeutic hypothesis. Projects must be clearly positioned within the preclinical phase, as the program explicitly excludes clinical trial activities. The anticipated opportunity is discretionary in nature and supports diverse research institutions, from state and local government agencies to higher education institutions and nonprofit organizations. The eligibility criteria are intentionally broad to encourage innovative, interdisciplinary collaboration across sectors. In addition to standard applicants like universities and hospitals, the NOFO allows submissions from for-profit entities, federally and non-federally recognized tribal governments, and non-domestic organizations. This inclusive eligibility framework aligns with NIH’s commitment to fostering a wide range of scientific perspectives and capabilities in addressing neurodegenerative diseases. Although applications are not being accepted at this time, the estimated post date for the full NOFO is July 31, 2026, with an application due date expected on October 5, 2026. The projected award date is July 1, 2027, with the project period commencing the same day. These advance dates are shared to give research teams time to form collaborations, develop project concepts, and align resources for submission readiness. There are no pre-application stages (e.g., LOI or concept paper) currently indicated. The evaluation criteria for this NOFO are not yet detailed but are expected to align with standard NIH review processes, emphasizing scientific merit, innovation, approach, investigator qualifications, and environment. As with other NIH U01 opportunities, applicants should anticipate significant involvement from NIH program officials in project oversight. Prospective applicants are encouraged to engage with the program early, and inquiries can be directed to the NIA Scientific Contact via email at [email protected]. Overall, this funding opportunity seeks to catalyze early-stage drug discovery by validating promising new therapeutic targets for AD and ADRD. The NIA aims to accelerate the development of transformative treatments by investing in the scientific groundwork that precedes clinical testing. Interested applicants should monitor Grants.gov and NIH resources for the formal release and further instructions.